aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
3.285
+0.185 (5.97%)
Apr 21, 2025, 4:00 PM EDT - Market closed
aTyr Pharma Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
1,217.55
Revenue / Employee
$3,615
Employees
65
Market Cap
291.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
Dec 31, 2022 | 10.39M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ATYR News
- 18 days ago - aTyr Pharma to Participate in April Investor Conferences - GlobeNewsWire
- 25 days ago - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewsWire
- 5 weeks ago - aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
- 5 weeks ago - aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - GlobeNewsWire
- 6 weeks ago - aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - GlobeNewsWire